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Abstract
Background Mediastinal lymph node staging for lung cancer
remains one ofthe mostimportant factors todetermine patient
outcome.
Methods Noninvasive imaging techniques such as CT, MRI,
PETandPET-CTprovidesomeanswersbutnotissuediagnosis.
Results The development of endo-oesophageal (EUS) and
endobronchial ultrasound (EBUS) with fine-needle aspiration
has provided the clinician with a tool to investigate the
mediastinum and the adrenal gland with a safe, minimally
invasiveprocedurethatcanbeperformedonanoutpatientbasis.
Conclusion The aim of this article was to give radiologists
an overview of the techniques of EUS and EBUS and their
role in the staging of lung cancer patients.
Keywords Endo-oesophageal ultrasound.Endobronchial
ultrasound.Lung cancer
Introduction
Lung cancer is still the leading cause of cancer mortality
worldwide with a poor overall survival rate. In the diagnosis
of lung cancer mediastinal lymph node sampling is important
for adequate staging in order to determine appropriate
treatment as well as predicting outcome [1]. Apart from that,
adequate staging of lung cancer is also important in order to
improve research into lung cancer, for accurate comparison
of data and for quality control. Noninvasive radiological
staging can aid in the initial assessment of metastatic spread
but lymph node sampling will still need to be performed to
determine nodal infiltration. Mediastinoscopy used to be the
gold standard for nodal sampling, but other techniques such
as endobronchial ultrasound and endo-oesophageal ultra-
sound are playing a bigger role in obtaining tissue samples
from mediastinal lymph nodes.
The TNM staging for lung cancer has recently been
revised (Table 1), with the downstaging of a number of
nodal stations. N0 describes no nodal spread; N1 represents
spread to the ipsilateral intrapulmonary, hilar or peribron-
chial lymph nodes; N2 staging involves ipsilateral or
subcarinal mediastinal nodes; N3 status describes contra-
lateral mediastinal or supraclavicular nodes.
For an overview of mediastinal lymph nodes, see Fig. 1
[2]. Lymph node stations 3a and b are not demonstrated
here as they are visualised only on a lateral view.
Imaging of the mediastinum
Computed tomography (CT), magnetic resonance imaging
(MRI), positron emission tomography (PET) and PET-CTare
useful noninvasive imaging techniques for the staging of lung
cancer; however, they are not sufficiently sensitive or specific
to determine mediastinal lymph node involvement [3–7]. CT
is usually the initial method for staging of the mediastinal
nodes. According to national and international guidelines,
however, only lymph nodes with a short axis diameter over a
size of 1 cm (± positivity in PET if performed as a PET-CT
for example) are usually considered to have suspected
malignant involvement judged by radiological criteria.
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accurate than PET alone [8]. Given the high false-positive
rate in CT and PET-CT [3], however, and the fact that these
tests do not provide a tissue diagnosis, it is important to
obtain lymph node tissue to determine operability.
Guidelines suggest that positive PET findings within the
mediastinum should be confirmed with invasive techniques
before any operative procedure [4, 9, 10]. Even when PET
is negative, invasive staging ought to be considered if the
tumour is central, positive N1 nodes on CTor PETare seen,
positive mediastinal nodes on CT are seen or if there is low
FDG uptake in the primary tumour [9, 10].
One study comparing PET/CT and endobronchial
ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA) in lymph node staging showed the diag-
nostic accuracy of PET/CT to be 62.4% and that of EBUS-
TBNA to be 97.4% [3, 5].
Tissue sampling techniques in the mediastinum
Cervical mediastinoscopy has been the gold standard for
mediastinal staging for many years and has shown a pooled
Fig. 1 Lymph node stations in the mediastinum. Lymph node stations
3a and b are only visible on side views and not accessible by
endobronchial ultrasound (EBUS) or endoscopic ultrasound (EUS)
Table 1 TNM staging table; the new changes are highlighted in grey, adjusted from Detterbeck et al. [2]
T and M N0 N1 N2 N3
UICC6 and Descriptor New T/M Stage Stage Stage Stage
T1 (<=2cm) T1a IA IIA IIIA IIIB
T1 (>2 – 3 cm) T1b IA IIA IIIA IIIB
T2 (<5cm) T2a IB IIA IIIA IIIB
T2 (>5-7cm) T2b IIA IIB IIIA IIIB
T2 (>7cm)
T3
IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension)
T4
IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural effusion)
M1a
IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
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Only certain lymph node stations are accessible (1, 2, 3, 4
and anterior 7), while access to the posterior and inferior
mediastinum is limited and requires extended cervical
mediastinoscopy or thoracoscopy. Even with these proce-
dures, it is not possible to evaluate the hilar lymph nodes.
Since mediastinoscopy is an invasive and expensive
procedure, requiring general anaesthesia and an operating
theatre, less invasive techniques such as endobronchial
ultrasound and endo-oesophageal ultrasound have been
developed over the last few years.
Endobronchial ultrasound
Developed in 2002, the EBUS bronchoscope (models
Olympus BF-UC160F-OL8 or BF-UC260F-OL8 and Pen-
tax EB-1970 UK) looks similar to a normal bronchovideo-
scope, and the smallest available diameter is currently
6.3 mm wide with a 2.2-mm working or instrument channel
and a 30-degree side viewing optic. Furthermore, a curved
linear array ultrasonic transducer sits on the distal end
(Fig. 2) and can be used either with direct contact to the
mucosal surface or via an inflatable balloon, which can be
attached at the tip. This allows a conventional endoscopic
picture side-by-side with the ultrasound view. Ultrasound is
performed at a frequency of 7.5–12 MHz with tissue
penetration of 20–50 mm. A dedicated ultrasound processor
creates the ultrasound image.
Endobronchial ultrasound allows the bronchoscopist to
visualise airway structures as well as surrounding tissue. It
is very valuable for staging of advanced cancer with regard
to intramural or nodal spread. EBUS can identify N2 and
N3 nodes without the need for surgical intervention. An
additional advantage is the high resolution of mediastinal
structures to show tumour invasion and to diagnose intra-
pleural tumours. At the same time colour Doppler as well as
power Doppler can be used to identify surrounding vascular
structures. The images obtained are generally easier to
interpret than those of radial endobronchial ultrasound
probes (Fig. 3).
Different needles of 21- and 22-gauge are available and
can be advanced through the working channel of the EBUS
scope (Fig. 4) in order to puncture lymph nodes under real-
time ultrasound visualisation. The needle has an internal
stylet to avoid contamination with bronchial wall mucosa
Fig. 2 Distal end of the EBUS Scope. With permission from
Olympus, Tokyo, Japan
Fig. 3 EBUS image with lymph node and adjacent pulmonary artery
in power Doppler mode
Fig. 4 Olympus EBUS Scope with TBNA (NA-201SX-4022) needle
attached
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control allow for a better yield in comparison to ‘blind’
needle aspiration (Fig. 5). Ideally three punctures [12]o f
each lymph node should be performed to achieve an
optimal yield.
Lymph node stations that can be reached via EBUS
are the highest mediastinal (station 1), upper paratracheal
(2L and 2R), lower paratracheal (4R and 4L), subcarinal
(station 7), hilar (station 10) as well as interlobar (station 11)
and lobar nodes (station 12). It is important to remember that
lymph node stations 5, 6, 8 and 9 are not routinely accessible
by this method. The highest staging lymph node should be
biopsied first; otherwise, the needle requires changing each
time to avoid contamination and false-positive results [13].
Lymph nodes at a size of 5 mm and upwards can be
successfully sampled and have to date been proven to have
excellent diagnostic yield. The learning curve for EBUS-
TBNA has been evaluated and recorded at ten supervised
procedures in order to achieve excellent sensitivity and
diagnostic accuracy [14].
In a recent meta-analysis EBUS-TBNA has been shown
to have a high pooled sensitivity of 93% and specificity of
100% [15]. Multiple publications provide evidence that
even in patients with lymph nodes under 1 cm (which had
been termed N0 by CT criteria), with the use of EBUS-
TBNA a large percentage could still be shown to have N2/
N3 disease (some despite also being negative on PET-CT)
[16–18].
Complications such as bleeding or infection are very rare
and have only been reported as case reports [19–21].
Endo-oesophageal ultrasound
Gastroenterologists have been using this technique for
many years in the investigation of oesophageal and
pancreatic malignancies. The linear EUS Scope (Olympus
GF-UC160P-OL5/GF-UCT160-OL5 or Pentax EG-
3830UT) has the same basic architecture as the EBUS
scope and uses a device with between 5 and 10 MHz
(Fig. 6). The tissue penetration of the ultrasound can be up
to 8 cm (Fig. 7). Endo-oesophageal ultrasound (EUS) is
especially useful in the staging of the posterior mediasti-
num, lymph node station 4L, 7, lower para-oesophageal
(station 8), inferior pulmonary ligament lymph nodes
(station 9) and coeliac lymph nodes. Lymph node stations
1L and 2L can also be reached. The left adrenal can be
identified in up to 97% [22] and has a so-called ‘seagull’
shape on ultrasound. It is particularly well visualised in cases
of metastatic enlargement (Fig. 8). Furthermore, the left lobe
of the liver can also be accessed. The hilar and precarinal
lymph nodes however cannot be reached, with lymph node
stations 2R, 3 and 4R only poorly accessible by EUS.
Fig. 5 EBUS needle being advanced into lymph node
Fig. 6 Distal end of the EUS Scope, with permission from Olympus,
Tokyo, Japan
Fig. 7 EUS image. With kind permission from J. Annema. Multiple
subcentimeter nodes between oesophagus (OE), aorta (AO) and
pulmonary artery (PA). This represents lymph node station 4 left
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equipped with a stylet. Different types of needles are
available for EUS, such as Medi-Globe, Olympus and Cook
needles. The procedure is usually performed on an
outpatient basis and takes approximately 30 min.
As with EBUS, the puncture of lymph nodes is
performed under real-time ultrasound guidance.
Endo-oesophageal ultrasound is more accurate and has a
higher predictive value than either PET or CT for posterior
mediastinal lymph nodes [23], and multiple publications as
well as a meta-analysis on endo-oesophageal ultrasound
fine-needle aspiration (EUS-FNA) have shown a high
sensitivity and specificity [23–25]. Even in patients without
mediastinal lymph node enlargement on CT, EUS-FNA has
been able to demonstrate metastases in 25% of lung cancer
patients [16, 26].
The procedure carries only a very small risk of media-
stinitis or bleeding. Unless cysts are punctured, antibiotics do
not need to be administered routinely [27, 28].
Combining EBUS and EUS
A comparison of the range of sampling sites between EUS-
FNA with EBUS-TBNA as shown in Table 2 highlights the
fact that EUS and EBUS provide access to different areas of
the mediastinum and also differing approaches to nodal
stations, and are thought of as complementary procedures.
In combining both techniques, most lymph node stations as
well as the left adrenal gland can be reached (apart from
stations 3, 5 and 6). In six recent series the accuracy of
EUS-FNA and EBUS-TBNA used in combination for the
diagnosis of mediastinal cancer was 95% [29–34]. Using
the EBUS scope for both endobronchial as well as endo-
oesophageal sampling, the sensitivity for cancer detection
was shown to be as high as 96% (EUS 89%, EBUS 91),
with a specificity of 100% and negative predictive value of
96% (EUS 82%, EBUS 92%) [33].
Rapid on-site evaluation (ROSE) of the material
obtained further increases the yield and has been shown
to be cost-effective [35]. A cytopathologist screens the
needle aspirates in the endoscopy suite for the presence of
diagnostic material, ensuring adequate samples are obtained
before ending the procedure. When a positive sample is
collected, the procedure can be abandoned, thus avoiding
unnecessary multiple punctures of lymph nodes.
It is important to remember however that with EBUS
and EUS the negative predictive value is under discussion.
The guidelines available [9, 10] currently recommend that
samples that do not contain tumour cells require follow-up
with a more definitive procedure such as mediastinoscopy
or video-assisted thoracoscopy (VATS). Recent publications
however [33, 34] suggest that the negative predictive value
has improved significantly and therefore may no longer be
an issue.
Application of endoscopic ultrasound in routine practice
The main barrier to the routine use of EBUS and EUS in
staging lung cancer is the variable procedure reimburse-
ment seen in different countries as well as inconsistent
introduction into national or local guidelines.
To date most of these procedures have been performed
at centres of excellence, and results on sensitivity and
specificity are only available from these centres rather
than from routine use at smaller hospitals. Competency
in these techniques is becoming more common however,
and with this wider practice more consistent utilisation
should be possible. The guidelines with regard to how to
achieve and maintain competency are currently under
discussion.
Fig. 8 EUS picture of enlarged left adrenal gland. With kind
permission from J. Annema. Ma=stomach, M=left adrenal gland,
LNi=left kidney
Table 2 Comparison of the range of tissue sampling sites between
endo-oesophageal ultrasound fine-needle aspiration (EUS-FNA) and
endobronchial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA)
EUS EBUS
Mediastinal staging (N2/N3) ++ ++
Mediastinal restaging (N2/N3) + +
Hilar staging (N1/N3) - ++
Intrapulmonary tumours (T) + +
Tumour invasion (T4) (central vessels) + -/+
Left adrenal gland (M1) + -
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important to note that the results of the biopsies depend
largely on the availability of a trained cytopathologist,
which might impede development in some institutions.
As previously mentioned, even though with the combi-
nation of both techniques most lymph node stations within
the mediastinum can be reached, stations 3, 5 and 6 are not
accessible to either technique and may require more
invasive staging.
Decision tree for staging the mediastinum
With different staging techniques in lung cancer available
to the physician, we propose a decision tree as shown in
Fig. 9. The initial staging procedure should be a CTor PET-
CT as both are easily available and noninvasive. If then
there is a need for tissue confirmation the procedure should
be EUS, EBUS or a combination of both depending on
which lymph node stations need to be reached. As per the
guidelines the next step should be mediastinoscopy in cases
of negative cytology from the lymph node sampling.
Restaging of the mediastinum
Accurate restaging of the mediastinum is important in
patients with stage III disease following induction chemo-
radiotherapy to consider whether these patients would
benefit from surgery. The discussion continues as to which
technique ought to be applied to achieve the best sensitivity
and specificity [36, 37].
Response evaluation of the mediastinum by serial CT
after induction therapy can be difficult as gross residual
tumour may be present at surgery despite stable disease on
CT [38]. The sensitivity and specificity for PET-CT in the
Fig. 9 Proposed decision tree
n Sensitivity (%) Specificity (%) Accuracy (%)
PET [44] 8 trials 380 59 85
MES 3 trials 204 71 100 81
EUS [45, 46] 2 trials 58 70–75 96–100 86–92
EBUS [47, 48] 2 trials 185 67–76 86–100 77–80
Table 3 Comparison of
sensitivity, specificity and
accuracy of PET, mediastino-
scopy (MES), EUS and EBUS
for restaging the mediastinum in
lung cancer
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the initial mediastinal lymph node staging [39–41]. How-
ever, researchers have recently looked at the percentage
change in SUVmax rather than the size of the lymph nodes
or lesion, and found that if this decreases by more than 80%
a complete response can be predicted with 96% accuracy
[42]. Repeat mediastinoscopy for restaging is also a
valuable tool despite the fact that sensitivity and accuracy
are lower than for the first procedure [43].
The value of EBUS-TBNA and EUS-FNA in restaging
of the mediastinum was evaluated in four different
publications, demonstrating a high sensitivity, specificity
and accuracy for these techniques (Table 3).
As mentioned before, the adequate restaging technique
remains a matter of debate, as the comparison of the different
techniques is still problematic. Endoscopic techniques are
safe, minimally invasive and produce accurate results in
comparison to surgical data from re-mediastinoscopy. Never-
theless, if needle aspiration is negative, surgical restaging is
required to adequately assess the mediastinum before any
decision is made to carry out surgery.
Conclusion
Overall, EBUS and EUS are both safe and effective
techniques for the staging of the mediastinum, allowing a
reduction in the number of invasive staging procedures.
Previously the main limitations to EBUS and EUS were
that they used to be predominantly performed at centres of
excellence and hence only on selected patients. Nowadays,
though, more and more physicians and surgeons are trained
in these techniques. Training remains an issue, and
performance of an adequate amount of procedures per year
is required in order to maintain competency. Reimburse-
ment for these procedures can pose a further problem in
some countries as well as the actual introduction into cancer
guidelines within the hospitals.
Increasingly, however, both techniques are being used in
hospitals across the world, improving the diagnostic yield.
EBUS and EUS ought to be regarded as the first-line
techniques for investigating the mediastinum.
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